Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable)

NCT00242749 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00242749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2002
Completion date
July 31, 2007
Enrollment
47
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of head and neck